Portal de investigación
A Phase 2, Randomized, Open-Label Study of Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256).
Datos básicos
Documentos
- No hay documentos
Grupos
Financiadores - Promotores
INCYTE CORPORATION
Cita
A Phase 2, Randomized, Open-Label Study of Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256). (INCA034176-256). INCYTE CORPORATION. 2025IP:JOSÉ MARÍA FERNÁNDEZ NAVARRO.